K Number
K061699
Device Name
EXCIA
Manufacturer
Date Cleared
2006-08-18

(63 days)

Product Code
Regulation Number
888.3360
Reference & Predicate Devices
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The Excia Hip System is intended to replace a hip joint.

The device is intended for:

  • Patients suffering from severe hip pain and disability due to rheumatoid arthritis, . osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral head and nonunion of previous fractures of the femur.
  • Patients with congenital hip dysplasia, protrusion acetabuli, or slipped capital femoral . ephiphysis
  • Patients suffering from disability due to previous fusion ●
  • Patients with acute femoral neck fractures .

The Excia Hip System is available with two femoral stems. One is manufactured from CoCr and intended for cemented fixation. The other femoral stem is for uncemented fixation and is manufactured from Ti. With a Ti. Plasma spray.

Device Description

The Acetabular Cups (Plasmacup® NSC and MSC) are manufactured from Ti. and are offered with a plasmapore® coating. The Plasmacup® is offered in two designs: NSC and MSC (no holes or multiple holes). Both designs are available in sizes ranging from 40mm - 68mm. The new Plasmacup® Acetabular Cups are a line extension to the existing Excia Total Hip System.

The Excia Hip System is available with two femoral stems. One is manufactured from CoCr and intended for cemented fixation. The other femoral stem is for uncemented fixation and is manufactured from Ti. With a Ti. Plasma spray.

AI/ML Overview

This document is a 510(k) Premarket Notification for a line extension of the Excia Total Hip System, specifically for new Acetabular Cups (Plasmacup® NSC and MSC). This submission is for a medical device and thus does not include information about artificial intelligence (AI) performance, study design, or expert review panels typically found in AI/ML medical device submissions.

Therefore, I cannot provide the requested information regarding acceptance criteria and a study proving device meets acceptance criteria as these pertain to AI/ML device performance and are not present in this 510(k) submission.

This submission focuses on demonstrating substantial equivalence to a predicate device based on similar technological characteristics (material, shape, size) and compliance with relevant orthopedic device testing guidance documents, not on performance criteria measured through clinical studies or AI algorithm evaluation.

Key points from the document indicating a lack of AI/ML information:

  • Device Type: The device is a "Total Hip System Line Extension," specifically acetabular cups, which are physical orthopedic implants.
  • Performance Data: The "PERFORMANCE DATA" section states that "All required testing per 'Draft Guidance for the Preparation of Premarket Notifications (510(k)s) Applications for Orthopedic Devices-The Basic Elements' were done where applicable." It then lists several guidance documents related to testing orthopedic implants, metallic surfaces, modular components, acetabular cup prostheses, femoral stem prostheses, ceramic ball hip systems, and UHMWPE. These are all related to mechanical, material, and biocompatibility testing of physical implants, not AI/ML algorithm performance.
  • No mention of AI/ML: There is no mention of software, AI, algorithms, diagnostic performance (e.g., sensitivity, specificity), ground truth, training sets, test sets, or expert review in the context of an AI/ML-driven device.
  • Substantial Equivalence: The primary goal of this 510(k) is to demonstrate "Substantial Equivalence" to the predicate device (Plasmacup® SC) based on similar design and materials.

Therefore, all requested sections related to acceptance criteria, study details, sample sizes, ground truth, and expert review directly applicable to AI/ML performance cannot be filled from the provided document.

{0}------------------------------------------------

Excia Toatal Hip System Line Extension

Special 510(k) Premarket Notification

.

AUG 1 8 2006

Page 1 of 1

B. 510(k) SUMMARY (as required by 21 CFR 807.92)

Excia Total Hip System Line Extension June 13, 2006

1042

K061699

COMPANY:Aesculap®, Inc.3773 Corporate ParkwayCenter Valley, PA 18034Establishment Registration Number: 291671-
CONTACT:Lisa M. Boyle610-984-9274 (phone)610-791-6882 (fax)
TRADE NAME:Excia
COMMON NAME:Excia Total Hip System
DEVICE CLASS:Class II
REGULATION NUMBER:888.3353, 888.3350, 888.3360
PRODUCT CODE:LZO, JDI, and LWJ
REVIEW PANEL:Orthopedic

SUBSTANTIAL EQUIVALENCE

Aesculap®, Inc. believes that the Acetabular Cups (Plasmacup® NSC and MSC) are substantially equivalent to the Acetabular Cups (Plasmacup® SC) that are cleared in the Excia Total Hip System (K042334).

DEVICE DESCRIPTION

The Acetabular Cups (Plasmacup® NSC and MSC) are manufactured from Ti. and are offered with a plasmapore® coating. The Plasmacup® is offered in two designs: NSC and MSC (no holes or multiple holes). Both designs are available in sizes ranging from 40mm - 68mm. The new Plasmacup® Acetabular Cups are a line extension to the existing Excia Total Hip System.

INDICATIONS FOR USE

The Excia Hip System is intended to replace a hip joint.

The device is intended for:

  • Patients suffering from severe hip pain and disability due to rheumatoid arthritis, . osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral head and nonunion of previous fractures of the femur.
  • Patients with congenital hip dysplasia, protrusion acetabuli, or slipped capital femoral . ephiphysis

{1}------------------------------------------------

Special 510(k) Premarket Notification

  • . Patients suffering from disability due to previous fusion
    14061699

  • Patients with acute femoral neck fractures �
    The Excia Hip System is available with two femoral stems. One is manufactured from CoCr and intended for cemented fixation. The other femoral stem is for uncemented fixation and is manufactured from Ti. With a Ti. Plasma spray,

TECHNOLIGICAL CHARACTERISTICS (compared to Predicate(s)}

The new Plasmacup® NSC and MSC acetabular cups of the Excia Total Hip System are offered in similar shapes and sizes as the predicate devices. The material used for the Aescualp device is the same as that used to manufacture the predicate device.

PERFORMANCE DATA

All required testing per "Draft Guidance for the Preparation of Premarket Notifications (510(k)s) Applications for Orthopedic Devices-The Basic Elements" were done where applicable. In addition, testing per the;

  • "Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces . Apposing Bone or Bone Cement",
  • "Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on . Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements",
  • "Guidance Document for Testing Non-articulating, "Mechanically Locked" Modular . Implant Components",
  • "Draft Guidance Document for Testing Acetabular Cup Prostheses", .
  • "Points to Consider for Femoral Stem Prostheses", �
  • "Guidance Document for the Preparation of Premarket Notifications for Ceramic Ball ◆ Hip Systems and
  • "Data Requirements for Ultrahigh Molecular Weight Poletheylene (UHMWPE) Used . in Orthopedic Devices" was completed where applicable.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the Department of Health and Human Services, USA. The logo features a stylized eagle with three stripes forming its body and wings. The eagle is facing left. The text "DEPARTMENT OF HEALTH AND HUMAN SERVICES, USA" is arranged in a circular pattern around the eagle.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 1 8 2006

Aesculap, Inc. % Ms. Lisa M. Boyle Regulatory Specialist 3773 Corporate Parkway Center Valley, Pennsylvania 18034

Re: K061699

Trade/Device Name: Excia Total Hip System Line Extension Regulation Number: 21 CFR 888.3353 Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis Regulatory Class: Class II Product Code: LZO, JDI, LWJ Dated: July 25, 2006 Received: July 26, 2006

Dear Ms. Boyle:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

{3}------------------------------------------------

Page 2 - Ms. Lisa M. Boyle

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Kaitaque Spuchund

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Special 510(k) Premarket Notification

Page 1 of 1

A. INDICATIONS FOR USE STATEMENT

510(k) Number: _______________________________________________________________________________________________________________________________________________________________

Device Name: Excia Total Hip System Line Extension

Indications for Use:

The Excia Hip System is intended to replace a hip joint.

The device is intended for:

  • Patients suffering from severe hip pain and disability due to rheumatoid arthritis, . osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral head and nonunion of previous fractures of the femur.
  • Patients with congenital hip dysplasia, protrusion acetabuli, or slipped capital femoral . ephiphysis
  • Patients suffering from disability due to previous fusion ●
  • Patients with acute femoral neck fractures .

The Excia Hip System is available with two femoral stems. One is manufactured from CoCr and intended for cemented fixation. The other femoral stem is for uncemented fixation and is manufactured from Ti. With a Ti. Plasma spray.

Prescription UseXand/or Over-the-Counter Use
(per 21 CFR 801 Subpart D)(per 21 CFR 801 Subpart C)

Barbara Bush

CONSE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) (Division Signeering DO NOT WRITE BELOW THIS LINE - CORPINGE ON ANTHER PAGE
Division of General, Restorative, and Neurological Devices

510(k) NumberK061999
------------------------

§ 888.3360 Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis.

(a)
Identification. A hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis is a device intended to be implanted to replace a portion of the hip joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum. This generic type of device includes designs which are intended to be fixed to the bone with bone cement (§ 888.3027) as well as designs which have large window-like holes in the stem of the device and which are intended for use without bone cement. However, in these latter designs, fixation of the device is not achieved by means of bone ingrowth.(b)
Classification. Class II.